381 related articles for article (PubMed ID: 34372572)
21. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Izumi T; Shirakawa K; Takaori-Kondo A
Mini Rev Med Chem; 2008 Mar; 8(3):231-8. PubMed ID: 18336343
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
23. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
24. Feline Immunodeficiency Virus Evolutionarily Acquires Two Proteins, Vif and Protease, Capable of Antagonizing Feline APOBEC3.
Yoshikawa R; Takeuchi JS; Yamada E; Nakano Y; Misawa N; Kimura Y; Ren F; Miyazawa T; Koyanagi Y; Sato K
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331087
[TBL] [Abstract][Full Text] [Related]
25. Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population.
Ezzikouri S; Kitab B; Rebbani K; Marchio A; Wain-Hobson S; Dejean A; Vartanian JP; Pineau P; Benjelloun S
J Viral Hepat; 2013 Oct; 20(10):678-86. PubMed ID: 24010642
[TBL] [Abstract][Full Text] [Related]
26. Species-specific differences in the ability of feline lentiviral Vif to degrade feline APOBEC3 proteins.
Yoshikawa R; Nakano Y; Yamada E; Izumi T; Misawa N; Koyanagi Y; Sato K
Microbiol Immunol; 2016 Apr; 60(4):272-9. PubMed ID: 26935128
[TBL] [Abstract][Full Text] [Related]
27. Elucidation of the Complicated Scenario of Primate APOBEC3 Gene Evolution.
Uriu K; Kosugi Y; Suzuki N; Ito J; Sato K
J Virol; 2021 May; 95(12):. PubMed ID: 33789992
[TBL] [Abstract][Full Text] [Related]
28. Footprint of the host restriction factors APOBEC3 on the genome of human viruses.
Poulain F; Lejeune N; Willemart K; Gillet NA
PLoS Pathog; 2020 Aug; 16(8):e1008718. PubMed ID: 32797103
[TBL] [Abstract][Full Text] [Related]
29. Characterization of APOBEC3 variation in a population of HIV-1 infected individuals in northern South Africa.
Matume ND; Tebit DM; Gray LR; Turner SD; Rekosh D; Bessong PO; Hammarskjöld ML
BMC Med Genet; 2019 Jan; 20(1):21. PubMed ID: 30660178
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
31. [Antiviral defense by APOBEC3 family proteins].
Takaori A
Uirusu; 2005 Dec; 55(2):267-72. PubMed ID: 16557012
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
33. [APOBEC3s: history of an antiviral and mutagenic protein family].
Verriez C; Marquet R; Paillart JC; Stupfler B
Virologie (Montrouge); 2020 Dec; 24(6):381-418. PubMed ID: 33441290
[TBL] [Abstract][Full Text] [Related]
34. APOBEC3-induced mutation of the hepatitis virus B DNA genome occurs during its viral RNA reverse transcription into (-)-DNA.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Patterson AP
J Biol Chem; 2021 Aug; 297(2):100889. PubMed ID: 34181944
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R; Strebel K
Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
[TBL] [Abstract][Full Text] [Related]
36. The Battle between Retroviruses and APOBEC3 Genes: Its Past and Present.
Uriu K; Kosugi Y; Ito J; Sato K
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477360
[TBL] [Abstract][Full Text] [Related]
37. A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.
Cheng AZ; Moraes SN; Attarian C; Yockteng-Melgar J; Jarvis MC; Biolatti M; Galitska G; Dell'Oste V; Frappier L; Bierle CJ; Rice SA; Harris RS
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534038
[TBL] [Abstract][Full Text] [Related]
38. APOBEC: A molecular driver in cervical cancer pathogenesis.
Revathidevi S; Murugan AK; Nakaoka H; Inoue I; Munirajan AK
Cancer Lett; 2021 Jan; 496():104-116. PubMed ID: 33038491
[TBL] [Abstract][Full Text] [Related]
39. The APOBEC3 family of retroelement restriction factors.
Refsland EW; Harris RS
Curr Top Microbiol Immunol; 2013; 371():1-27. PubMed ID: 23686230
[TBL] [Abstract][Full Text] [Related]
40. Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.
Zhao W; Akkawi C; Mougel M; Ross SR
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
